Kantarjian HM - Search Results

1

Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia.

Kantarjian HM, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthukar G, Faderl S, Garcia-Manero G, Kadia T, Sankhala K, Odenike O, Altman JK, Minden M. Kantarjian HM, et al. Invest New Drugs. 2012 Jun;30(3):1107-15. doi: 10.1007/s10637-011-9660-2. Epub 2011 Apr 15. Invest New Drugs. 2012. PMID: 21494838 Free PMC article. Clinical Trial.

2

Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor.

Estey EH, Dixon D, Kantarjian HM, Keating MJ, McCredie K, Bodey GP, Kurzrock R, Talpaz M, Freireich EJ, Deisseroth AB, et al. Estey EH, et al. Among authors: kantarjian hm. Blood. 1990 May 1;75(9):1766-9. Blood. 1990. PMID: 2184901 Free article.

3

Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia.

Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB, Freireich EJ. Kantarjian HM, et al. Cancer. 1989 Mar 1;63(5):813-7. doi: 10.1002/1097-0142(19890301)63:5<813::aid-cncr2820630502>3.0.co;2-v. Cancer. 1989. PMID: 2914287

4

Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.

Anderlini P, Benjamin RS, Wong FC, Kantarjian HM, Andreeff M, Kornblau SM, O'Brien S, Mackay B, Ewer MS, Pierce SA, et al. Anderlini P, et al. Among authors: kantarjian hm. J Clin Oncol. 1995 Nov;13(11):2827-34. doi: 10.1200/JCO.1995.13.11.2827. J Clin Oncol. 1995. PMID: 7595745

5

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.

Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ, et al. Kantarjian HM, et al. Blood. 1993 Mar 1;81(5):1146-51. Blood. 1993. PMID: 8382970 Free article. Clinical Trial.

6

Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.

Anderlini P, Luna M, Kantarjian HM, O'Brien S, Pierce S, Keating MJ, Estey EH. Anderlini P, et al. Among authors: kantarjian hm. Leukemia. 1996 Apr;10(4):600-8. Leukemia. 1996. PMID: 8618434 Clinical Trial.

7

Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.

Kantarjian HM, Beran M, O'Brien S, Robertson L, Siddik Z, Yoshida M, Yang LY, Rios MB, Keating MJ, Meyer M, et al. Kantarjian HM, et al. Leukemia. 1996 Mar;10(3):396-401. Leukemia. 1996. PMID: 8642853 Clinical Trial.

8

Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.

Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E. Kornblau SM, et al. Among authors: kantarjian hm. Leukemia. 1996 Oct;10(10):1563-9. Leukemia. 1996. PMID: 8847890 Clinical Trial.

9

Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia.

Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Faderl S, et al. Among authors: kantarjian hm. Blood. 1998 Jun 1;91(11):3995-4019. Blood. 1998. PMID: 9596644 Free article. Review. No abstract available.

10

A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission.

Cortes JE, Kantarjian HM, O'Brien S, Giles F, Keating MJ, Freireich EJ, Estey EH. Cortes JE, et al. Among authors: kantarjian hm. Cancer. 1999 Apr 1;85(7):1506-13. Cancer. 1999. PMID: 10193940 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,047 results

Search Page

Filters